Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial

Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.

Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of $(0.76) per share

8-K filing — Keros Therapeutics, Inc. (KROS)

Filed: 2026-08-03 AccNo: 0001664710-26-000050 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated Symptoms

Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.

Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’

Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more human-relevant methods.